Treatments & Clinical Trials

What We Learned From New Research on GLP-1s and Alzheimer’s – and What’s on the Horizon

From the clinic to home: FDA approves at-home Leqembi® injections

A new study reports that a blood test was 91% effective at diagnosing Alzheimer’s disease. What should I know?

FDA Approval of Donanemab Marks Major Advance in Alzheimer’s Treatment

Independent advisors to the FDA recommend Eli Lilly’s Alzheimer’s drug donanemab

New Drug Donanemab Shows Promise: Advancements in Early Alzheimer’s Treatment

Introducing Leqembi: What You Need to Know About This Breakthrough in the Fight Against Alzheimer’s Disease

FAQ About Leqembi

Promising Breakthrough in Alzheimer’s Treatment: Donanemab Study Results

Cognitive-Behavioral Therapy: A Powerful Tool for Memory Loss and Cognitive Symptoms

Understanding Cognitive Therapy: A Comprehensive Guide to Cognitive Remediation and Rehabilitation

FDA Approves New Alzheimer’s Drug, Leqembi